Axoltis Pharma receives authorization to launch SEALS – phase II clinical trial for ALS patients with drug candidate NX210c

Phase II trial will assess efficacy and tolerability of NX210c in Amyotrophic Lateral Sclerosis (ALS) patients 80 patients due to be enrolled with first results expected in early 2026 NX210c drug candidate allows for promising approach to repairing Blood Brain Barrier (BBB) which is impaired in neurodegenerative diseases such as ALS Read more (Download PDF English / Français )

The release as fetched from its publisher. axoltis.com ↗